Outside the submitted work, she has received grants and/or personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GI Dynamics, Intarcia, Mannkind, Merck, Mylan, Novartis, NovoNordisk, Pfizer, Sanofi, TARGETPharma, and Valeritas
Expert Support at Weight Medics At Weight Medics , our bespoke treatment plans go beyond the injection
Key Structural Differences# Head-to-Head: LEAD-6 Trial# The LEAD-6 trial (Buse et al., Lancet 2009) directly compared liraglutide 1.8 mg once daily with exenatide 10 mcg twice daily in 464 adults with type 2 diabetes inadequately controlled on metformin, sulfonylurea, or both over 26 weeks: Liraglutide was statistically superior for glycemic control and demonstrated better tolerability, with less persistent nausea and fewer hypoglycemia events
Despite these potential risks, discontinuation rates due to the adverse impacts remain low, highlighting the tolerability and effectiveness of GLP-1 agonists for most clients